EPCAM and metastatic neoplasm: We found an elevated proportion and number of CD133+ cells in the blood of patients with metastatic disease, while cells expressing EpCAM were significantly depleted in patients with metastases (median value: 0.0015 vs. 0.0046 % in patients without metastases; p = 0.012; Fig. 5).